Articles

On September 21, 2022, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›

Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›

Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›

Ovarian cancer is the fifth leading cause of cancer death among women in the United States. Read More ›

Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing. Read More ›

Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team. Read More ›

All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit. Read More ›

In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer. Read More ›

In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment. Read More ›

CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation. Read More ›